This description perfectly fits not only our preclinical data, but also what we observed in patients, where high expression of SIRT6 correlates with a significantly worse prognosis of HER2-positive breast cancer patients, in particular those with grade 3 tumors. Here, SIRT6 is linked to breast carcinoma.